"Oystershell, Ghent-based healthcare company, appoints new CEO"
Ghent, 30 April 2020 - Oystershell, an innovative player in the pharmaceutical industry for consumers, announces the appointment of Mike Van Ganse as new CEO. With more than 25 years experience in the health care business, Van Ganse is looking to take the dynamic organization to the next level.
"I am looking forward to heading up a company with such enormous growth potential”
Mike Van Ganse is a familiar figure in consumer healthcare. He has previously occupied senior marketing positions at Novartis, Bayer, Omega Pharma and Vision Healthcare, based in several different countries, and was the founder and CEO of jeCare.
On 1 May, Van Ganse will take up a full-time role as the new CEO of Oystershell, following the approval of his appointment by the Board of Directors. "I am looking forward to heading up a company with such enormous growth potential”, Van Ganse says.
Oystershell is an innovative player in the healthcare industry that specialises in developing and commercialising over-the-counter health care products. The firm has its own research & development team that develops innovative products, which is pretty unique for the sector. These products are commercialised under the company’s own brands (including Elimax, Pixie and Pistal) and under the brands of large multinationals.
With the support of shareholders (Gilde Buy Out Partners as main shareholder) and a highly motivated team, Mike Van Ganse will soon be starting work.
The goal is to further accelerate the growth seen in recent years by bringing the long and promising list of healthcare products that are still in the development phase onto the market, not only in Europe, but also in the United States and China. The appointment of Mike Van Ganse, with his solid international experience, will no doubt deliver great added value to Oystershell.
More Info? contact us